Anti-SLPI antibody [31] (ab17157)
Key features and details
- Mouse monoclonal [31] to SLPI
- Suitable for: IHC-Fr
- Reacts with: Human
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
Anti-SLPI antibody [31]
See all SLPI primary antibodies -
Description
Mouse monoclonal [31] to SLPI -
Host species
Mouse -
Specificity
The reactivity of the antibody with the isolated domains was evaluated using isolated domains of SLPI obtained by cleavage using partial acidic hydrolysis. Therefore, it is possible that the antibody will recognize other SLPI cleavage products generated by e.g. (microbial) proteases. -
Tested applications
Suitable for: IHC-Frmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length native protein (purified) corresponding to Human SLPI. SLPI purified from sputum
-
Positive control
- PMN lysate
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituents: PBS, 0.1% BSA -
Concentration information loading...
-
Clonality
Monoclonal -
Clone number
31 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab17157 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-Fr |
1/50.
|
Notes |
---|
IHC-Fr
1/50. |
Target
-
Function
Acid-stable proteinase inhibitor with strong affinities for trypsin, chymotrypsin, elastase, and cathepsin G. May prevent elastase-mediated damage to oral and possibly other mucosal tissues. -
Tissue specificity
Mucous fluids. -
Sequence similarities
Contains 2 WAP domains. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 6590 Human
- GenBank: NM_003064 Human
- Omim: 107285 Human
- SwissProt: P03973 Human
- Unigene: 517070 Human
-
Alternative names
- ALK 1 antibody
- ALK1 antibody
- ALP antibody
see all
Images
Datasheets and documents
-
Datasheet download
References (6)
ab17157 has been referenced in 6 publications.
- Wei Z et al. Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells. Discov Oncol 14:1 (2023). PubMed: 36595102
- McElvaney OF et al. Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. EBioMedicine 77:103894 (2022). PubMed: 35217407
- Huang Y et al. Reduced Expression of Antimicrobial Protein Secretory Leukoprotease Inhibitor and Clusterin in Chronic Rhinosinusitis with Nasal Polyps. J Immunol Res 2021:1057186 (2021). PubMed: 33506054
- Jin Y et al. Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-?B and Akt pathways. Cancer Cell Int 19:220 (2019). PubMed: 31462893
- Xu CB et al. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor ß1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor. J Cell Biochem N/A:N/A (2019). PubMed: 30706537
- Wang X et al. Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. Oncol Rep 39:1793-1804 (2018). PubMed: 29436667